{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:20:56Z","timestamp":1788009656061,"version":"build-2784847793"},"reference-count":67,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn\u2019s disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.<\/jats:p>","DOI":"10.1093\/ecco-jcc\/jjab185","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T18:35:13Z","timestamp":1634754913000},"page":"ii64-ii72","source":"Crossref","is-referenced-by-count":90,"title":["Blockade of IL-23: What is in the Pipeline?"],"prefix":"10.1093","volume":"16","author":[{"given":"Tommaso Lorenzo","family":"Parigi","sequence":"first","affiliation":[{"name":"Institute of Immunology and Immunotherapy NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Iacucci","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy NIHR Birmingham Biomedical Research Centre, University Hospitals NHS Foundation Trust and University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-7797","authenticated-orcid":false,"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[{"name":"APC Microbiome Ireland Centre, College of Medicine and Health, University College Cork, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"2022051214002473800_CIT0001","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"key":"2022051214002473800_CIT0002","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.4049\/jimmunol.154.10.5071","article-title":"Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells","volume":"154","author":"Macatonia","year":"1995","journal-title":"J Immunol"},{"key":"2022051214002473800_CIT0003","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"},{"key":"2022051214002473800_CIT0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022051214002473800_CIT0005","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"J Exp Med"},{"key":"2022051214002473800_CIT0006","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"2022051214002473800_CIT0007","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.immuni.2015.12.003","article-title":"Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions","volume":"43","author":"Patel","year":"2015","journal-title":"Immunity"},{"key":"2022051214002473800_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"2022051214002473800_CIT0009","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"2022051214002473800_CIT0010","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"2022051214002473800_CIT0011","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J Clin Invest"},{"key":"2022051214002473800_CIT0012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2008.10.018","article-title":"RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F","volume":"136","author":"Leppkes","year":"2009","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"2022051214002473800_CIT0014","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1097\/MIB.0b013e3182a563cb","article-title":"Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease","volume":"19","author":"Ohman","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2022051214002473800_CIT0015","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20061082","article-title":"IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis","volume":"203","author":"Kullberg","year":"2006","journal-title":"J Exp Med"},{"key":"2022051214002473800_CIT0016","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"2022051214002473800_CIT0017","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2022051214002473800_CIT0018","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"2022051214002473800_CIT0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022051214002473800_CIT0020","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"2022051214002473800_CIT0021","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn\u2019s disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2022051214002473800_CIT0022","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/j.1468-3083.2012.04705.x","article-title":"Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12\/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis","volume":"27","author":"Langley","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022051214002473800_CIT0023","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0024","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"2022051214002473800_CIT0025","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2022051214002473800_CIT0026","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1053\/j.gastro.2018.06.035","article-title":"Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn\u2019s disease","volume":"155","author":"Rutgeerts","year":"2018","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0027","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2022051214002473800_CIT0028","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1053\/j.gastro.2020.08.037","article-title":"Relationship between combined histologic and endoscopic endpoints and efficacy of ustekinumab treatment in patients with ulcerative colitis","volume":"159","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0029","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.14309\/01.ajg.0000705428.10562.bf","article-title":"S0845 pharmacokinetics and immunogenicity of maintenance therapy with Ustekinumab: 2-year results from the UNIFI long-term extension study","volume":"115","author":"Adedokun","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2022051214002473800_CIT0030","article-title":"Real","volume":"3","author":"Hong","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2022051214002473800_CIT0031","doi-asserted-by":"crossref","first-page":"S1200","DOI":"10.14309\/01.ajg.0000711124.92899.10","article-title":"S2269 efficacy of intravenous Ustekinumab as induction therapy for patients hospitalized with severe inflammatory bowel disease: a case series","volume":"115","author":"Hooper","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2022051214002473800_CIT0032","doi-asserted-by":"crossref","first-page":"S1197","DOI":"10.14309\/01.ajg.0000711092.60286.73","article-title":"S2261 combining cyclosporine with Ustekinumab in acute severe ulcerative colitis: report of 2 cases","volume":"115","author":"Shaffer","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2022051214002473800_CIT0033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of Ustekinumab treatment of Crohn\u2019s disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2022051214002473800_CIT0034","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/apt.16119","article-title":"Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy","volume":"52","author":"Panaccione","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2022051214002473800_CIT0035","doi-asserted-by":"crossref","first-page":"S-37","DOI":"10.1016\/S0016-5085(21)00834-9","article-title":"Safety of Ustekinumab in IBD: a comprehensive analysis of major cardiovascular events (MACE) through 5 years in CD and 2 years in UC","volume":"160","author":"Ghosh","year":"2021","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0036","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"2022051214002473800_CIT0037","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"2022051214002473800_CIT0038","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of Guselkumab versus Adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"2022051214002473800_CIT0039","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of Risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022051214002473800_CIT0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"2022051214002473800_CIT0041","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41385-019-0146-4","article-title":"Induction of autophagy in Cx3cr1+ mononuclear cells limits IL-23\/IL-22 axis-mediated intestinal fibrosis","volume":"12","author":"Mathur","year":"2019","journal-title":"Mucosal Immunol"},{"key":"2022051214002473800_CIT0042","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ecco-jcc\/jjy099","article-title":"Selective IL-23 inhibition by Risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn\u2019s disease: results from a randomised phase II biopsy sub-study","volume":"12","author":"Visvanathan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022051214002473800_CIT0043","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051214002473800_CIT0044","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor Risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"2022051214002473800_CIT0045","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022051214002473800_CIT0046","article-title":"Long-term safety and efficacy of Risankizumab treatment in patients with Crohn\u2019s disease: results from the phase 2 open-label extension study","author":"Ferrante","journal-title":"J Crohns Colitis"},{"key":"2022051214002473800_CIT0047","first-page":"E28","article-title":"Risankizumab induction therapy in patients with moderate-to-severe Crohn\u2019s disease with intolerance or inadequate response to conventional and\/or biologic therapy: results from the phase 3 advance study","volume-title":"Gastroenterology","author":"D\u2019Haens","year":"2021"},{"key":"2022051214002473800_CIT0048"},{"key":"2022051214002473800_CIT0049","first-page":"S033","article-title":"Risankizumab therapy induces improvements in endoscopic endpoints in patients with moderate-to-severe Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE studies","volume-title":"J Crohns Colitis","author":"Bossuyt","year":"2021"},{"key":"2022051214002473800_CIT0050","first-page":"S026","article-title":"Risankizumab induces early clinical remission and response in patients with moderate-to-severe Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE studies","volume-title":"J Crohns Colitis","author":"Schreiber","year":"2021"},{"key":"2022051214002473800_CIT0051","author":"AbbVie.","year":"2021"},{"key":"2022051214002473800_CIT0052","doi-asserted-by":"crossref","first-page":"e14487","DOI":"10.1111\/dth.14487","article-title":"Efficacy and safety of Risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis","volume":"34","author":"Singh","year":"2021","journal-title":"Dermatol Ther"},{"key":"2022051214002473800_CIT0053"},{"key":"2022051214002473800_CIT0054","author":"AbbVie","year":"2021"},{"key":"2022051214002473800_CIT0055","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of continued treatment with Mirikizumab in a phase 2 trial of patients with ulcerative colitis","author":"Sandborn","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022051214002473800_CIT0057","first-page":"S-S-1205","article-title":"Impact of Mirikizumab treatment on health-related quality of life in patients with ulcerative colitis: a phase 2 study analysis using the SF-36 V2 Standard","volume":"158","author":"Lichtenstein","year":"2020","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0058","first-page":"10","article-title":"Efficacy and safety of Mirikizumab (LY3074828) in a phase 2 study of patients with Crohn\u2019s disease","volume":"7","author":"Sands","year":"2019","journal-title":"United Eur Gastroent"},{"key":"2022051214002473800_CIT0059","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.14309\/01.ajg.0000704868.06216.e9","article-title":"Evaluation of symptom improvement during induction in patients with Crohn\u2019s disease treated with Mirikizumab","volume":"115","author":"Sandborn","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2022051214002473800_CIT0060","doi-asserted-by":"crossref","first-page":"S-37","DOI":"10.1016\/S0016-5085(21)00835-0","article-title":"Efficacy and safety of Mirikizumab after 52-weeks maintenance treatment in patients with moderate-to-severe Crohn\u2019s disease","volume":"160","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0061","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"2022051214002473800_CIT0062","first-page":"S027","article-title":"The effect of Guselkumab induction therapy on early clinical outcome measures in patients with moderately to severely active Crohn\u2019s disease: results from the phase 2 GALAXI 1 study","author":"Danese","year":"2021"},{"key":"2022051214002473800_CIT0063","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"2022051214002473800_CIT0064","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14740338.2018.1488963","article-title":"A safety evaluation of Guselkumab for the treatment of psoriasis","volume":"17","author":"Galluzzo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"2022051214002473800_CIT0065","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.14309\/01.ajg.0000592540.43886.35","article-title":"Safety, tolerability, and pharmacokinetics of PTG-200, an oral GI-restricted peptide antagonist of IL-23 receptor, in normal healthy volunteers","volume":"114","author":"Cheng","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2022051214002473800_CIT0066","article-title":"The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in preclinical model of IBD.","author":"Cheng"},{"key":"2022051214002473800_CIT0067","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/Supplement_2\/ii64\/43679582\/jjab185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/Supplement_2\/ii64\/43679582\/jjab185.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T12:15:05Z","timestamp":1699704905000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/Supplement_2\/ii64\/6584458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":67,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2022,5,11]]},"published-print":{"date-parts":[[2022,5,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab185","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,4,1]]}}}